Exelixis, Inc. (NASDAQ:EXEL) Shares Acquired by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. boosted its stake in Exelixis, Inc. (NASDAQ:EXEL) by 5.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,832 shares of the biotechnology company’s stock after buying an additional 1,150 shares during the period. E Fund Management Co. Ltd.’s holdings in Exelixis were worth $524,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in EXEL. Alaska Permanent Fund Corp increased its stake in shares of Exelixis by 1.5% in the third quarter. Alaska Permanent Fund Corp now owns 40,855 shares of the biotechnology company’s stock valued at $893,000 after purchasing an additional 596 shares during the period. Fifth Third Bancorp raised its stake in Exelixis by 44.2% during the 3rd quarter. Fifth Third Bancorp now owns 1,970 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 604 shares in the last quarter. Signaturefd LLC boosted its position in Exelixis by 17.1% during the 3rd quarter. Signaturefd LLC now owns 4,577 shares of the biotechnology company’s stock worth $100,000 after acquiring an additional 668 shares during the period. Fisher Asset Management LLC grew its stake in shares of Exelixis by 232.6% in the fourth quarter. Fisher Asset Management LLC now owns 1,041 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 728 shares in the last quarter. Finally, Treasurer of the State of North Carolina increased its holdings in shares of Exelixis by 0.5% during the third quarter. Treasurer of the State of North Carolina now owns 145,343 shares of the biotechnology company’s stock valued at $3,176,000 after purchasing an additional 738 shares during the period. 85.27% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Exelixis

In other news, Director David Edward Johnson acquired 190,000 shares of Exelixis stock in a transaction dated Wednesday, February 21st. The stock was acquired at an average cost of $20.70 per share, for a total transaction of $3,933,000.00. Following the completion of the purchase, the director now owns 1,100,730 shares of the company’s stock, valued at $22,785,111. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Exelixis news, Director David Edward Johnson purchased 190,000 shares of the company’s stock in a transaction on Wednesday, February 21st. The shares were bought at an average cost of $20.70 per share, with a total value of $3,933,000.00. Following the transaction, the director now directly owns 1,100,730 shares in the company, valued at approximately $22,785,111. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Patrick J. Haley sold 47,020 shares of the stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $21.45, for a total value of $1,008,579.00. Following the completion of the sale, the executive vice president now directly owns 384,866 shares of the company’s stock, valued at $8,255,375.70. The disclosure for this sale can be found here. Corporate insiders own 2.85% of the company’s stock.

Exelixis Stock Down 2.5 %

EXEL stock traded down $0.56 during trading hours on Wednesday, hitting $21.59. The company’s stock had a trading volume of 2,209,821 shares, compared to its average volume of 2,322,132. The stock has a 50 day moving average price of $22.98 and a two-hundred day moving average price of $22.24. Exelixis, Inc. has a 12 month low of $18.52 and a 12 month high of $24.34. The company has a market capitalization of $6.29 billion, a PE ratio of 33.73, a price-to-earnings-growth ratio of 0.59 and a beta of 0.57.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings results on Tuesday, April 30th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.28 by ($0.16). Exelixis had a return on equity of 8.85% and a net margin of 11.10%. The company had revenue of $425.23 million for the quarter, compared to the consensus estimate of $461.04 million. During the same quarter last year, the company posted $0.12 EPS. The business’s revenue was up 4.0% compared to the same quarter last year. Sell-side analysts expect that Exelixis, Inc. will post 1.17 earnings per share for the current year.

Wall Street Analyst Weigh In

EXEL has been the subject of a number of recent analyst reports. TheStreet upgraded shares of Exelixis from a “c+” rating to a “b-” rating in a research report on Monday, March 18th. TD Cowen boosted their target price on Exelixis from $25.00 to $27.00 and gave the stock a “buy” rating in a report on Wednesday, May 1st. William Blair reaffirmed an “outperform” rating on shares of Exelixis in a research note on Wednesday, May 1st. JMP Securities reiterated a “market outperform” rating and set a $27.00 price target on shares of Exelixis in a research report on Wednesday, April 10th. Finally, Royal Bank of Canada upped their price objective on Exelixis from $26.00 to $28.00 and gave the company an “outperform” rating in a report on Wednesday, February 7th. Six analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $26.33.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.